Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Raw Materials: 2021-2025

Historic Raw Materials for Veracyte (VCYT) over the last 4 years, with Sep 2025 value amounting to $20.3 million.

  • Veracyte's Raw Materials rose 25.60% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year increase of 25.60%. This contributed to the annual value of $17.9 million for FY2024, which is 346.90% up from last year.
  • Latest data reveals that Veracyte reported Raw Materials of $20.3 million as of Q3 2025, which was up 1.31% from $20.1 million recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Raw Materials peaked at $20.3 million during Q3 2025, and registered a low of $3.0 million during Q4 2021.
  • Moreover, its 3-year median value for Raw Materials was $12.2 million (2024), whereas its average is $11.4 million.
  • Its Raw Materials has fluctuated over the past 5 years, first dropped by 6.82% in 2023, then spiked by 346.90% in 2024.
  • Quarterly analysis of 5 years shows Veracyte's Raw Materials stood at $3.0 million in 2021, then skyrocketed by 36.67% to $4.1 million in 2022, then decreased by 2.44% to $4.0 million in 2023, then skyrocketed by 346.90% to $17.9 million in 2024, then grew by 25.60% to $20.3 million in 2025.
  • Its Raw Materials stands at $20.3 million for Q3 2025, versus $20.1 million for Q2 2025 and $18.4 million for Q1 2025.